JP2022533705A5 - - Google Patents

Info

Publication number
JP2022533705A5
JP2022533705A5 JP2021569042A JP2021569042A JP2022533705A5 JP 2022533705 A5 JP2022533705 A5 JP 2022533705A5 JP 2021569042 A JP2021569042 A JP 2021569042A JP 2021569042 A JP2021569042 A JP 2021569042A JP 2022533705 A5 JP2022533705 A5 JP 2022533705A5
Authority
JP
Japan
Prior art keywords
antibody
complement
neuropathy
antigen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533705A (ja
JP7607590B2 (ja
Filing date
Publication date
Priority claimed from GB1907153.9A external-priority patent/GB2584105B/en
Application filed filed Critical
Publication of JP2022533705A publication Critical patent/JP2022533705A/ja
Publication of JP2022533705A5 publication Critical patent/JP2022533705A5/ja
Priority to JP2024220534A priority Critical patent/JP2025038109A/ja
Priority to JP2024221343A priority patent/JP2025041724A/ja
Application granted granted Critical
Publication of JP7607590B2 publication Critical patent/JP7607590B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569042A 2019-05-21 2020-05-21 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト Active JP7607590B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024220534A JP2025038109A (ja) 2019-05-21 2024-12-17 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト
JP2024221343A JP2025041724A (ja) 2019-05-21 2024-12-18 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1907153.9A GB2584105B (en) 2019-05-21 2019-05-21 Methods of treating neuropathy
GB1907153.9 2019-05-21
PCT/EP2020/064234 WO2020234432A1 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024220534A Division JP2025038109A (ja) 2019-05-21 2024-12-17 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト
JP2024221343A Division JP2025041724A (ja) 2019-05-21 2024-12-18 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト

Publications (3)

Publication Number Publication Date
JP2022533705A JP2022533705A (ja) 2022-07-25
JP2022533705A5 true JP2022533705A5 (cg-RX-API-DMAC7.html) 2023-05-31
JP7607590B2 JP7607590B2 (ja) 2024-12-27

Family

ID=67385155

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021569042A Active JP7607590B2 (ja) 2019-05-21 2020-05-21 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト
JP2024220534A Pending JP2025038109A (ja) 2019-05-21 2024-12-17 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト
JP2024221343A Pending JP2025041724A (ja) 2019-05-21 2024-12-18 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024220534A Pending JP2025038109A (ja) 2019-05-21 2024-12-17 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト
JP2024221343A Pending JP2025041724A (ja) 2019-05-21 2024-12-18 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト

Country Status (21)

Country Link
EP (2) EP4570316A3 (cg-RX-API-DMAC7.html)
JP (3) JP7607590B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220010505A (cg-RX-API-DMAC7.html)
CN (2) CN114269382B (cg-RX-API-DMAC7.html)
AU (2) AU2020279543B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138401A1 (cg-RX-API-DMAC7.html)
DK (1) DK3972643T3 (cg-RX-API-DMAC7.html)
EA (1) EA202193189A1 (cg-RX-API-DMAC7.html)
ES (1) ES3035736T3 (cg-RX-API-DMAC7.html)
FI (1) FI3972643T3 (cg-RX-API-DMAC7.html)
GB (1) GB2584105B (cg-RX-API-DMAC7.html)
HU (1) HUE072743T2 (cg-RX-API-DMAC7.html)
IL (1) IL288010A (cg-RX-API-DMAC7.html)
LT (1) LT3972643T (cg-RX-API-DMAC7.html)
MA (1) MA71752A (cg-RX-API-DMAC7.html)
MX (2) MX2021014170A (cg-RX-API-DMAC7.html)
PL (1) PL3972643T3 (cg-RX-API-DMAC7.html)
PT (1) PT3972643T (cg-RX-API-DMAC7.html)
SG (1) SG11202112232YA (cg-RX-API-DMAC7.html)
WO (1) WO2020234432A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3893924T3 (pl) * 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
CN117597353A (zh) * 2021-03-18 2024-02-23 艾菲洛之克公司 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION
EP4059949A1 (en) * 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
US20240166692A1 (en) * 2021-03-18 2024-05-23 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
MX2024008273A (es) * 2021-12-30 2024-07-19 Annexon Inc Composiciones y metodos para el tratamiento de la enfermedad de huntington.
MA71448A (fr) * 2022-07-14 2025-04-30 argenx BV Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm)
EP4676952A2 (en) * 2023-03-07 2026-01-14 The Cleveland Clinic Foundation Human complement component 2 binding molecules
WO2025146509A1 (en) * 2024-01-05 2025-07-10 argenx BV Methods of treating multifocal motor neuropathy (mmn)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2008030505A2 (en) * 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
LT3028716T (lt) * 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体関連障害を処置するための方法および組成物
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
PL2753636T3 (pl) * 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
CN102949719A (zh) * 2012-04-28 2013-03-06 上海市徐汇区中心医院 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1
WO2014096958A1 (en) * 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
US9944717B2 (en) 2013-05-23 2018-04-17 Broteio Pharma B.V. Binding molecules that bind human complement factor C2 and uses thereof
WO2015089368A2 (en) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
PL3215527T3 (pl) * 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
CN108026134A (zh) * 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
WO2017196960A1 (en) * 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
SG11201907583TA (en) * 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
CA3078971A1 (en) * 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
PL3893924T3 (pl) * 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania

Similar Documents

Publication Publication Date Title
US11167038B2 (en) Methods for improving safety of blood-brain barrier transport
JP7071349B2 (ja) ピログルタメートアミロイド-βに対する抗体及びその使用
JP5695317B2 (ja) 抗体媒介性ニューロパシーを処置するための方法および組成物
KR101999872B1 (ko) 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
CN107074965B (zh) 特异性结合微管相关蛋白tau的抗体和抗原结合片段
ES2756649T3 (es) Anticuerpos contra tau y usos de los mismos
JP2020007318A5 (cg-RX-API-DMAC7.html)
JP2021191267A5 (cg-RX-API-DMAC7.html)
FI3972643T3 (fi) Komplementtijärjestelmän antagonisteja käytettäväksi paraproteinemisten neuropatioiden hoitomenetelmissä
AU2011336716A1 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
CN109562167A (zh) 联合治疗
WO2021212049A2 (en) Anti-sars-cov-2 monoclonal antibodies
CN102037018A (zh) 识别结合了抗原的抗体与没有结合抗原的抗体的结构变化的抗体及其获得方法
CN107001452A (zh) 用于治疗癌症的抗ck8抗体
JP2023537078A5 (cg-RX-API-DMAC7.html)
CN114605532B (zh) 抗β-淀粉样蛋白抗体及其用途
CN114594272B (zh) 用于检测β-淀粉样蛋白的产品和方法
JP5683466B2 (ja) 抗psk抗体
CN119546631A (zh) 用于治疗支气管扩张的抗PcrV和Psl双特异性抗体
NZ781789B2 (en) Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
CN114591429B (zh) 结合β-淀粉样蛋白的抗体及其用途
HK40063067B (en) Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
HK1191341B (en) Low affinity blood brain barrier receptor antibodies and uses therefor
HK1259793B (en) Methods for improving safety of blood-brain barrier transport